Bristol-Myers Squibb Company BMY

Company Overview

Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical company focused on the discovery, development, licensing, manufacture, and commercialization of innovative medicines. The company operates primarily within the pharmaceuticals and biotechnology industries, with a strategic emphasis on oncology, hematology, cardiovascular, immunology, and neuroscience. Its business model is centered on developing branded, patent-protected therapies that address serious diseases with high unmet medical needs.

The company’s primary revenue drivers are prescription medicines, including blockbuster therapies such as Opdivo, Eliquis, Revlimid, Pomalyst, Orencia, and Yervoy. Bristol-Myers Squibb serves hospitals, specialty clinics, physicians, and government and commercial payers globally. Its strategic positioning is built on a strong research and development (R&D) pipeline, deep expertise in biologics and immuno-oncology, and long product life cycles supported by regulatory exclusivity. Founded in 1887, the company evolved through organic R&D growth and transformative acquisitions, most notably the acquisition of Celgene Corporation in 2019, which significantly expanded its oncology and hematology portfolio.